GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced that the US Government will purchase an additional 600,000 doses of sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, enabling further nationwide access to sotrovimab for patients.
New Vaxzevria data further support its use as third dose booster
- Details
- Category: AstraZeneca
Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a third dose booster, increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants, while a separate analysis of samples from the trial showed increased antibody response to the Omicron variant.
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
- Details
- Category: Novartis
Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo to treat COVID-19, met the primary endpoint of viral load reduction over eight days. The two secondary endpoints also showed clinically meaningful benefit over placebo - (1) composite endpoint of hospitalization and/or Emergency Room (ER) visits or death, and (2) time to sustained clinical recovery.
Amgen and Arrakis Therapeutics announce multi-target collaboration to identify novel RNA degrader small molecule therapeutics
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a range of difficult-to-drug targets in multiple therapeutic areas. This new class of "targeted RNA degraders" consists of small molecule drugs that selectively destroy RNAs encoding disease-causing proteins by inducing their proximity to nucleases.
Bayer and Mammoth Biosciences to collaborate on novel gene editing technolog
- Details
- Category: Bayer
Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboration and option agreement for the use of Mammoth's CRISPR systems to develop in vivo gene-editing therapies.
Pfizer and BioNTech sign new global collaboration agreement to develop first mRNA-based shingles vaccine
- Details
- Category: Business
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV), a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime.
Leiden University Medical Center and Intravacc to start clinical trial with new intranasal corona vaccine
- Details
- Category: Business
Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with Dutch Leiden University Medical Center (LUMC) to develop and evaluate a new nasal spray corona vaccine in a clinical phase I/II study.
More Pharma News ...
- Pfizer and BioNTech receive U.S. FDA Emergency Use Authorization of COVID-19 vaccine booster for individuals 12 years of age and older
- AstraZeneca and Ionis close agreement to develop and commercialise eplontersen
- Vaxzevria significantly boosted antibody levels against Omicron
- European Commission grants conditional marketing authorization for Novavax COVID-19 vaccine
- Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in independent FDA study
- Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021
- Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate